Ajanta Pharma Full Year 2024 Earnings: EPS Beats Expectations
Ajanta Pharma (NSE:AJANTPHARM) Full Year 2024 Results
Key Financial Results
- Revenue: ₹42.1b (up 13% from FY 2023).
- Net income: ₹8.16b (up 39% from FY 2023).
- Profit margin: 19% (up from 16% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: ₹64.82 (up from ₹45.89 in FY 2023).
AJANTPHARM Post-Clinical Trial Products
- Pre-registration: 22.
- Approved (during full year): 6.
- Launched (during full year): 27.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ajanta Pharma EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.0%.
The primary driver behind last 12 months revenue was the Emerging Market segment contributing a total revenue of ₹16.4b (39% of total revenue). Explore how AJANTPHARM's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India.
Performance of the Indian Pharmaceuticals industry.
The company's shares are down 1.4% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 1 warning sign for Ajanta Pharma you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:AJANTPHARM
Ajanta Pharma
A specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages.
Outstanding track record with flawless balance sheet and pays a dividend.
